Season's greetings 2023
Dear partners and friends,
2023 has been an exciting year for Adamant Health. After several successful recruitments during spring, our team has been growing to 14 professionals dedicated to revolutionizing the care of Parkinson's disease. In addition, we have opened offices in Kuopio and Helsinki during 2023.
In the beginning of the year, Adamant Health has been selected for Business Finland's Deep Tech Accelerator funding program, as one of 17 promising deep tech startups. The Deep Tech Accelerator is a very important program to bring groundbreaking innovation to the market and disrupt entire industries. For Adamant Health, the funding will serve as a catalyst in accelerating our entry to selected European markets and drive our growth, particularly within our target customer segments including healthcare service providers and pharmaceutical companies. In addition, our project focusing on better understanding the life of patients with Parkinson's disease at home has received co-funding from the European Union.
In 2023, we have been spreading the word about our unique, research-based data-analysis technology for Parkinson's disease and other movement disorders providing detailed and accurate motor symptom data, essential for supporting personalized treatment that can be continuously optimized. Our technology, based on wearable surface electromyography (EMG) and 3D accelerometry, adds clinically meaningful data to the existing method of in-clinic evaluation by analyzing muscle activity and movement over a longer period of time. This gives an accurate insight into the patients’ condition and a clear picture of their symptoms.
In addition to participating in the major events for movement disorders and neurological diseases in Finland, we have launched our presence in Germany at the 96. Kongress der Deutschen Gesellschaft für Neurologie and globally at the International Congress of Parkinson's Disease and Movement Disorders 2023. We were very pleased to see that there was a lot of interest in our technology. Conference participants were keen to find out more about its possibilities and how it differentiates from measurement with 3D accelerometry only.
Adamant Health's service has also become available for test use in Finland and Germany during 2023. We are currently partnering with several clinics and rehabilitation centers in Finland and Germany, who are testing our service.
With the year drawing to an end, we’d like to take this opportunity to thank you for your cooperation and support throughout the year. As we pause to spend time with family and friends during the holidays, we wish you a happy, healthy holiday season and a wonderful New Year!
For 2024, we are looking forward to continuing our cooperation with you and educating the market about the benefits of bringing accuracy and clarity to the measurement of movement disorder symptoms. By providing clinically meaningful and actionable data, we will help neurologists improving their capabilities in making more informed treatment decisions and allow patients suffering from movement disorders to lead better lives!
The Adamant Health team